22 December 2025VideosBiotechnologyDirk Buehler, Maiwald

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Gilead to pay up to $5bn for antibody-drug conjugates push

8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.

Biotechnology

Closing the women's health gap offers ‘benefits for all’

7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

More features

Appeals court eases Teva’s headache with reversal

Cancer drug researcher hit with suit over mutation-targeting tools

LSPN Awards USA: Meet the judges

Gilead to pay up to $5bn for antibody-drug conjugates push

Closing the women's health gap offers ‘benefits for all’

UPC refuses early knockout in Illumina–Element dispute

CRISPR priority feud ends at USPTO as board reaches decision

Novartis bets $2bn on biologics as Xolair patents fade

WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?

More on this story

Editor's picks

Editor's picks

More features